Receptor-wise, the main difference between PACAP38 and VIP is the over 1000-fold higher affinity of PACAP38 to the PAC1 receptor (Table 1), which positions the PAC1 receptor as a potential novel target for migraine treatment [68]. Here, ADCYAP1 is linked to migraine disorder.